Advanced Aesthetic Technologies, Inc. (AAT), a leader in aesthetic gel implant technology, and China National Biotec Group (CNBG), a subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM). ) have announced the execution of strategic cooperation contracts. This new relationship is based on CNBG's recognition of AAT's products and AAT's recognition of CNBG's leading position in the field of biopharmaceuticals in China. And it establishes an in-depth cooperation partnership in equity and product participation. Under the agreement, CNBG will assume an important but non-controlling interest in AAT in exchange for an investment in AAT. And Lanzhou Biotechnique Development Co., LTD.,

CNBG is China's largest biopharmaceutical company and Lanzhou Company is the only botulinum toxin producer in China. Hengli® (LANTOX) is the leading botulinum toxin in the Chinese market, distributed to over 6,500 medical aesthetic institutions in China and holds over 75% of the Chinese BTXA market.

Advanced Aesthetic Technologies, Inc.'s Algeness® is a patented family of 100% natural, fully resorbable injectable gel implant dermal fillers offering safety, skin rejuvenation and natural-looking results at rest and during facial movements. Typical clinical advantages include minimal swelling after injection and immediately visible results. Algeness is CE marked and is currently distributed in over 30 countries. The AAT has initiated US FDA approval process.

AAT Board member in Los Angeles , California, plastic surgeon Brian M. Kinney , MD, FACS, said: "Algeness represents a soft tissue filling 'implant' that meets an unmet need for doctors and patients, for delivering immediate results but with minimal swelling, side effects, or impact on the immune system. In addition, it goes beyond simply providing volume to give projection or shape. My patients require safe, natural products with results in natural look and feel. Algeness has the potential to meet these patient demands in a new and innovative way. "